Pancreatic ductal adenocarcinoma: A review of immunologic aspects

Journal of Investigative Medicine

Volumn 60, Issue 4, 2012, Pages 643-663

  Wachsmann, Megan B ^a   Pop, Laurentiu M ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Immune; Immune response; Immunotherapy; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINASE; CD28 ANTIGEN; CD40 ANTIGEN; CHEMOKINE; COLONY STIMULATING FACTOR; COMPLEMENT INHIBITOR; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEATH RECEPTOR; ENDOSTATIN; FAS LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERFERON; MUCIN 1; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN BCL 2; RECEPTOR BINDING CANCER ANTIGEN 1; SGN 75; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL MIGRATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INSULIN TOLERANCE TEST; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MAST CELL; METASTASIS; MYELOID PROGENITOR CELL; NATURAL KILLER CELL; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC STELLATE CELL; PROTEIN EXPRESSION; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

HARNESS;

EID: 84860799288     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31824a4d79     Document Type: Review

References (313)

1. Matzinger P, Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev Immunol. 2011;11:221-230.
2. Schreiber RD, Old LJ, Sm-th MJ. Cancer immunoediting: integrating immunit-'s roles in cancer suppression and promotion. Science. 2011;331:1565-1570.
3. Emmrich J, Sparmann G, HoptU, et al. T-ping of leukoc-tes in pancreatic tissue surrounding human pancreatic carcinoma. Ann N Acad Sci. 1999;880:171-174. (Pubitemid 29349124)
4. Fogar P, Sperti C, Basso D, et al. Decreased total l-mphoc-te counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006;32:22-28. (Pubitemid 41803643)
5. Tassi E, Gavazzi F, Albarello L, et al. CarcinoembrYonic antigen-specific but not antiviral CD4+ T cell immunit is impaired in pancreatic carcinoma patients. J Immunol. 2008;181:6595-6603.
6. Bellone G, Turletti A, Artusio E, et al. TumorYassociated transforming growth factor-beta and interleukin-10 contribute to a s-stemic TH2 immune phenot-pe in pancreatic carcinoma patients. Am J Pathol. 1999;155:537-547. (Pubitemid 29370403)
7. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation b producing interleukin 17. Nat Immunol. 2005;6:1133-1141. (Pubitemid 41541791)
8. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammator and hematopoietic c-tokines. J Exp Med. 1996;183:2593-2603. (Pubitemid 26193037)
9. Gnerlich JL, Mitchem JB, Weir JS, et al. Induction of TH17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol. 2010;185:4063-4071.
10. Amamoto M, Kamigaki T, Amashita K, et al. Enhancement of anti-tumor immunit b high levels of TH1 and TH17 with a combination of dendritic cell fusion h-brids and regulator T cell depletion in pancreatic cancer. Oncol Rep. 2009;22:337-343.
11. Wilke CM, Kr-czek I, Wei S, et al. TH17 cells in cancer: help or hindrance? Carcinogenesis. 2011;32:643-649.
12. Ikemoto T, Yamaguchi T, Morine Y, et al. Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas. 2006;33:386-390. (Pubitemid 44690729)
13. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulator T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423-5434. (Pubitemid 44497257)
14. Yamagiwa S, Gry JD, Hashimoto S, et al. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulator T cells from human peripheral blood. J Immunol. 2001;166:7282-7289. (Pubitemid 32525603)
15. Baecher-Allan CM, Hafler DA. Functional anal-sis of highl defined, FACS-isolated populations of human regulator CD4+CD25+ T cells. Clin Immunol. 2005;117:192; discussion 193.
16. Tan MC, Goedegebuure PS, Bel BA, et al. Disruption of CCR5-dependent homing of regulator T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 2009;182:1746-1755.
17. Viehl CT, Moore TT, LiYanage UK, et al. Depletion of CD4+CD25+ regulator T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. Ann Surg Oncol. 2006;13:1252-1258. (Pubitemid 44440427)
18. Moo-Young TA, Larson JW, Belt BA, et al. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulator T cells in a murine model of pancreas cancer. J Immunother. 2009;32:12-21.
19. LiYanage UK, Goedegebuure PS, Moore TT, et al. Increased prevalence of regulator T cells (Treg) is induced b pancreas adenocarcinoma. J Immunother. 2006;29:416-424. (Pubitemid 44288954)
20. Lopez-Aleman R, Longstaff C, Hawle S, et al. Inhibition of cell surface mediated plasminogen activation b a monoclonal antibod against alphyEnolase. Am J Hematol. 2003;72:234-242. (Pubitemid 36383973)
21. Nakatsura T, Senju S, Ito M, et al. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originall defined b the SEREX method. Eur J Immunol. 2002;32:826-836. (Pubitemid 34257560)
22. Johnston FM, Tan MC, Tan BR Jr, et al. Circulating mesothelin protein and cellular antimesothelin immunit in patients with pancreatic cancer. Clin Cancer Res. 2009;15:6511-6518.
23. Barnd DL, Lan MS, Metzgar RS, et al. Specific, major histocompatibilit complex-unrestricted recognition of tumorYassociated mucins b human c-totoxic T cells. Proc Natl Acad Sci U S A. 1989;86:7159-7163. (Pubitemid 19240884)
24. Kotera Y, Fontenot JD, Pecher G, et al. Humoral immunit against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 1994;54:2856-2860. (Pubitemid 24187762)
25. Hamanaka Y, Suehiro Y, Fukui M, et al. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer. 2003;103:97-100. (Pubitemid 35424210)
26. Qin H, Chen W, Takahashi M, et al. CD4+ T-cell immunit to mutated ras protein in pancreatic and colon cancer patients. Cancer Res. 1995;55:2984-2987.
27. Shono Y, Tanimura H, Iwahashi M, et al. Specific T-cell immunit against Ki-ras peptides in patients with pancreatic and colorectal cancers. Br J Cancer. 2003;88:530-536. (Pubitemid 36363362)
28. Kubuschok B, Neumann F, Breit R, et al. Naturall occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res. 2006;12:1365-1372. (Pubitemid 43342530)
29. Imai K, Hirata S, Irie A, et al. Identification of a novel tumorYassociated antigen, cadherin 3/P-cadherin, as a possible target for immunotherap of pancreatic, gastric, and colorectal cancers. Clin Cancer Res. 2008;14:6487-6495.
30. Alters SE, Gadea JR, Philip R. Immunotherap of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. Adv Exp Med Biol. 1997;417:519-524.
31. Peiper M, Goedegebuure PS, Linehan DC, et al. The HER2/neu-derived peptide p654-662 is a tumorYassociated antigen in human pancreatic cancer recognized b c-totoxic T l-mphoc-tes. Eur J Immunol. 1997;27:1115-1123. (Pubitemid 27197213)
32. Argani P, Rost C, Reiter RE, et al. Discover of new markers of cancer through serial anal-sis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 2001;61:4320-4324. (Pubitemid 32685751)
33. Tanaka M, Komatsu N, Terakawa N, et al. Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients. Oncol Rep. 2007;18:161-166.
34. Marxsen J, Schmiegel W, Roder C, et al. Detection of the anti-p53 antibod response in malignant and benign pancreatic disease. Br J Cancer. 1994;70:1031-1034. (Pubitemid 24331109)
35. Raedle J, Oremek G, Welker M, et al. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas. 1996;13:241-246. (Pubitemid 26317992)
36. Schmitz-Winnenthal FH, Volk C, Z'Graggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 2005;65:10079-10087. (Pubitemid 41541490)
37. Fukunaga A, MiYamotok M, Cho Y, et al. CD8+ tumor-infiltrating l-mphoc-tes together with CD4+ tumor-infiltrating l-mphoc-tes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28:e26-e31.
38. Lund FE, Randall TD. Effector and regulator B cells: modulators of CD4(+) T cell immunit-. Nat Rev Immunol. 2010;10:236-247.
39. Raulet DH, Guerra N. Oncogenic stress sensed b the immune s-stem: role of natural killer cell receptors. Nat Rev Immunol. 2009;9:568-580.
40. Sutlu T, Alici E. Natural killer cell-based immunotherap in cancer: current insights and future prospects. J Intern Med. 2009;266:154-181.
41. Perussia B. L-mphokineYactivated killer cells, natural killer cells and c-tokines. Curr Opin Immunol. 1991;3:49-55.
42. KitaYama J, Atomi Y, Nagawa H, et al. Functional anal-sis of TCR gamma delta+ T cells in tumour-infiltrating l-mphoc-tes (TIL) of human pancreatic cancer. Clin Exp Immunol. 1993;93:442-447. (Pubitemid 23276273)
43. Degrate L, Nobili C, Franciosi C, et al. Interleukin-2 immunotherap action on innate immunit cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch Surg. 2009;394:115-121.
44. Funa K, Nilsson B, Jacobsson G, et al. Decreased natural killer cell activit and interferon production b leucoc-tes in patients with adenocarcinoma of the pancreas. Br J Cancer. 1984;50:231-233. (Pubitemid 14061950)
45. Aparicio-Pages MN, Verspaget HW, Pena AS, et al. Natural killer cell activit in patients with adenocarcinoma in the upper gastrointestinal tract. J Clin Lab Immunol. 1991;35:27-32.
46. Frankel TL, Burns W, Rile J, et al. Identification and characterization of a tumor infiltrating CD56(+)/CD16(j) NK cell subset with specificit for pancreatic and prostate cancer cell lines. Cancer Immunol Immunother. 59:1757-1769.
47. Stangl S, Wortmann A, Guertler U, et al. Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKDYactivated NK cells. J Immunol. 2006;176:6270-6276.
48. Marincola FM, Da Pozzo LF, Drucker BJ, et al. Adoptive immunotherap of human pancreatic cancer with l-mphokineYactivated killer cells and interleukin-2 in a nude mouse model. Surger-. 1990;108:919-929. (Pubitemid 20385317)
49. Wagner K, Schulz P, Scholz A, et al. The targeted immunoc-tokine L19-IL2 efficientl inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res. 2008;14:4951-4960.
50. Houghton AM. The paradox of tumorYassociated neutrophils: fueling tumor growth with c-totoxic substances. Cell C-cle. 2010;9:1732-1737.
51. Aliustaoglu M, Bilici A, Seker M, et al. The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterolog-. 2010;57:640-645.
52. An X, Ding PR, Li -H, et al. Elevated neutrophil to l-mphoc-te ratio predicts survival in advanced pancreatic cancer. Biomarkers. 2010;15:516-522.
53. Ten Kate M, Aalbers AG, SluiterW, et al. Pol-morphonuclear leukoc-tes increase the adhesion of circulating tumor cells to microvascular endothelium. Anticancer Res. 2007;27:17-22. (Pubitemid 46363310)
54. Bausch D, Pausch T, Krauss T, et al. Neutrophil granuloc-te derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis. 2011;14:235-243.
55. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A. 2006;103:12493-12498. (Pubitemid 44267286)
56. Khazaie K, Blatner N, Khan M, et al. The significant role of mast cells in cancer. Cancer Metastasis Rev. 2011;30:45-60.
57. Boesiger Jr, Tsai M, Maurer M, et al. Mast cells can secrete vascular permeabilit factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-independent upregulation of Fč receptor I expression. J Exp Med. 1998;188:1135-1145. (Pubitemid 28443337)
58. Esposito I, Menicagli M, Funel N, et al. Inflammator cells contribute to the generation of an angiogenic phenot-pe in pancreatic ductal adenocarcinoma. J Clin Pathol. 2004;57:630-636. (Pubitemid 38725766)
59. Strouch MJ, Cheon EC, Salabat MR, et al. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res. 2010;16:2257-2265.
60. Gabrilovich DI, Nagaraj S. M-eloid-derived suppressor cells as regulators of the immune s-stem. Nat Rev Immunol. 2009;9:162-174.
61. Almand B, Clark JI, Nikitina E, et al. Increased production of immature m-eloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678-689. (Pubitemid 32038493)
62. Bronte V, Chappell DB, Apolloni E, et al. Unopposed production of granuloc-te-macrophage colon-stimulating factor b tumors inhibits CD8+ T cell responses b d-sregulating antigen-presenting cell maturation. J Immunol. 1999;162:5728-5737. (Pubitemid 29314923)
63. Melani C, Chiodoni C, Forni G, et al. M-eloid cell expansion elicited b the progression of spontaneous mammar carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivit-. Blood. 2003;102:2138-2145. (Pubitemid 37122391)
64. Kusmartsev S, Cheng F, -u B, et al. All-trans-retinoic acid eliminates immature m-eloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63:4441-4449. (Pubitemid 36951016)
65. Oun JI, Nagaraj S, Collazo M, et al. Subsets of m-eloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181: 5791-5802.
66. Condamine T, Gabrilovich DI. Molecular mechanisms regulating m-eloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32:19-25.
67. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced m-eloid-derived suppressor cell subpopulations with distinct T cell-suppressive activit-. Blood. 2008;111:4233-4244.
68. Gabrilovich DI, Velders MP, SotomaYor EM, et al. Mechanism of immune d-sfunction in cancer mediated b immature Gr-1+ m-eloid cells. J Immunol. 2001;166:5398-5406. (Pubitemid 32374159)
69. Otsuji M, Kimura Y, Aoe T, et al. Oxidative stress b tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A. 1996;93:13119-13124. (Pubitemid 26382779)
70. Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature m-eloid suppressor cells mediate the development of tumor-induced T regulator cells and T-cell anerg in tumor-bearing host. Cancer Res. 2006;66:1123-1131. (Pubitemid 43165981)
71. Serafini P, Borrello I, Bronte V. M-eloid suppressor cells in cancer: recruitment, phenot-pe, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006;16:53-65. (Pubitemid 43139709)
72. Li H, Han Y, Guo Q, et al. Cancer-expanded m-eloid-derived suppressor cells induce anerg of NK cells through membrane-bound TGF-A1. J Immunol. 2009;182:240-249.
73. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in m-eloid suppressor cells is induced b COX-2 in lung carcinoma. J Exp Med. 2005;202:931-939. (Pubitemid 41396893)
74. Ostrand-Rosenberg S. M-eloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunit-. Cancer Immunol Immunother. 2010;59:1593-1600.
75. Tseng WW, Winer D, Kenkel JA, et al. Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin Cancer Res. 2010;16:3684-3695.
76. Zhao F, Obermann S, von Wasielewski R, et al. Increase in frequenc of m-eloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunolog-. 2009;128:141-149.
77. Clark CE, Hingorani SR, Mick R, et al. D-namics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67:9518-9527. (Pubitemid 47535942)
78. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605-612. (Pubitemid 43165918)
79. Mantovani A, Ming WJ, Balotta C, et al. Origin and regulation of tumorYassociated macrophages: the role of tumor-derived chemotactic factor. Biochim Bioph-s Acta. 1986;865:59-67. (Pubitemid 16050203)
80. Lewis JS, Landers RJ, Underwood JC, et al. Expression of vascular endothelial growth factor b macrophages is up-regulated in poorl vascularized areas of breast carcinomas. J Pathol. 2000;192:150-158.
81. Sica A, Bronte V. Altered macrophage differentiation and immune d-sfunction in tumor development. J Clin Invest. 2007;117:1155-1166. (Pubitemid 46718400)
82. Murdoch C, Tazz-man S, Webster S, et al. Expression of Tie-2 b human monoc-tes and their responses to angiopoietin-2. J Immunol. 2007;178:7405-7411. (Pubitemid 46847468)
83. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18:349-355.
84. Kurahara H, Shinchi H, Mataki Y, et al. Significance of M2-polarized tumorYassociated macrophage in pancreatic cancer. J Surg Res. 2011;167:e211-e219.
85. M-tar B, Baj-Krz-worzeka M, Majka M, et al. Human monoc-tes both enhance and inhibit the growth of human pancreatic cancer in SCID mice. Anticancer Res. 2008;28:187-192. (Pubitemid 351362900)
86. M-tar B, Wolosz-n M, Szatanek R, et al. Tumor cell-induced deactivation of human monoc-tes. J Leukoc Biol. 2003;74:1094-1101. (Pubitemid 38040331)
87. Baran B, Bech-ne I, Siedlar M, et al. Blood monoc-tes stimulate migration of human pancreatic carcinoma cells in vitro: the role of tumour necrosis factorYalpha. Eur J Cell Biol. 2009;88:743-752.
88. Clark CE, Beatt GL, Vonderheide RH. Immunosurveillance of pancreatic adenocarcinoma: insights from geneticall engineered mouse models of cancer. Cancer Lett. 2009;279:1-7.
89. Watowich SS, Liu -J. Mechanisms regulating dendritic cell specification and development. Immunol Rev. 2010;238:76-92.
90. Ma Y, A-meric L, Locher C, et al. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol. doi:S0952-7915(10)00135-4 [pii] 10.1016/j.coi.2010. 09.008.
91. Dallal RM, Christakos P, Lee K, et al. Paucit of dendritic cells in pancreatic cancer. Surger-. 2002;131:135-138. (Pubitemid 34169537)
92. Yamamoto T, Yanagimoto H, Satoi S, et al. Circulating m-eloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. J Surg Res. doi:S0022-4804(10)00778-X [pii] 10.1016/j.jss.2010.09.027.
93. Tjomsland V, Spangeus A, Sandstrom P, et al. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammator factors released from the tumor. PLoS One. 2010;5:e13441.
94. Tjomsland V, Sandstrom P, Spangeus A, et al. Pancreatic adenocarcinoma exerts s-stemic effects on the peripheral blood m-eloid and plasmac-toid dendritic cells: an indicator of disease severit-? BMC Cancer. 2010;10:87.
95. Neesse A, Michl P, Frese KK, et al. Stromal biolog and therap in pancreatic cancer. Gut. 2011;60:861-868.
96. Reiser-Erkan C, Erkan M, Pan Z, et al. H-poxiyinducible protoYoncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2008;7:1352-1359.
97. Couvelard A, O'Toole D, Leek R, et al. Expression of h-poxiyinducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopatholog-. 2005;46:668-676. (Pubitemid 40834826)
98. Bissell MJ, Radisk D. Putting tumours in context. Nat Rev Cancer. 2001;1:46-54. (Pubitemid 33741880)
99. Korc M. Pancreatic cancerYassociated stroma production. Am J Surg. 2007;194:S84-S86.
100. Korc M, Chandrasekar B, Yamanaka Y, et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest. 1992;90:1352-1360.
101. Bachem MG, Schunemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis b stimulating proliferation and matrix s-nthesis of stellate cells. Gastroenterolog-. 2005;128:907-921. (Pubitemid 40523543)
102. Lohr M, Schmidt C, Ringel J, et al. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 2001;61:550-555. (Pubitemid 32128613)
103. Viny Kumar AKA, Fausto N, Mitchell RN. Robbins Basic Patholog-. 8th ed. Philadelphia, PA: Saunders Elsevier; 2007:70-72, 200-201.
104. Sipos B, Weber D, Ungefroren H, et al. Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced b h-poxia: an in vitro and in vivo stud-. Int J Cancer. 2002;102:592-600. (Pubitemid 35334466)
105. Schniewind B, Groth S, Sebens Muerkoster S, et al. Dissecting the role of TGF-beta t-pe I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. Oncogene. 2007;26: 4850-4862. (Pubitemid 47093169)
106. Duner S, Lopatko Lindman J, Ansari D, et al. Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatolog-. 2010;10:673-681.
107. Erkan M, Kleeff J, Gorbachevski A, et al. Periostin creates a tumor-supportive microenvironment in the pancreas b sustaining fibrogenic stellate cell activit-. Gastroenterolog-. 2007;132:1447-1464. (Pubitemid 46627568)
108. Phillips PA, McCarroll JA, Park S, et al. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. Gut. 2003;52:275-282. (Pubitemid 36115072)
109. Erkan M, Reiser-Erkan C, Michalski CW, et al. Cancer-stellate cell interactions perpetuate the h-poxiyfibrosis c-cle in pancreatic ductal adenocarcinoma. Neoplasia. 2009;11:497-508.
110. Phillips PA, Wu MJ, Kumar RK, et al. Cell migration: a novel aspect of pancreatic stellate cell biolog-. Gut. 2003;52:677-682. (Pubitemid 36528869)
111. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737-744.
112. O'Reill MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285. (Pubitemid 28015876)
113. Walter K, Omura N, Hong SM, et al. Overexpression of smoothened activates the sonic hedgehog signaling pathwy in pancreatic cancerYassociated fibroblasts. Clin Cancer Res. 2010;16:1781-1789.
114. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed b endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92:735-745. (Pubitemid 28155313)
115. Dallas NA, Fan F, Gry MJ, et al. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev. 2007;26:433-441. (Pubitemid 350115100)
116. We JS, Gry MJ, Fan F, et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer. 2005;93:233-241. (Pubitemid 41133210)
117. Hansel DE, Wilentz RE, -eo CJ, et al. Expression of neuropilin-1 in high-grade d-splasia, invasive cancer, and metastases of the human gastrointestinal tract. Am J Surg Pathol. 2004;28:347-356. (Pubitemid 38269568)
118. Muders MH. Neuropilin and neuropilin associated molecules as new molecular targets in pancreatic adenocarcinoma. Anticancer Agents Med Chem. 2011;11:442-447.
119. Dallas NA, Gry MJ, Xia L, et al. Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clin Cancer Res. 2008;14:8052-8060.
120. Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunit-: a bidirectional link potentiall relevant for the monitoring of antiangiogenic therap and the development of novel therapeutic combination with immunotherap-. Cancer Metastasis Rev. 2011;30:83-95.
121. Ding XZ, Fehsenfeld DM, Murph LO, et al. Ph-siological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization b activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas. 2000;21:310-320.
122. Kang SP, Saif MW. Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factoř Highlights from the "2010 ASCO Annual Meeting." Chicago, IL, USA. June 4-8, 2010. JOP. 2010;11:334-335.
123. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters b metformin. Gastroenterolog-. 2001;120:1263-1270. (Pubitemid 32246678)
124. Bergmann U, Funatomi H, Kornmann M, et al. Increased expression of insulin receptor substrate-1 in human pancreatic cancer. Biochem Bioph-s Res Commun. 1996;220:886-890. (Pubitemid 26198607)
125. Kornmann M, MaruYama H, Bergmann U, et al. Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res. 1998;58:4250-4254. (Pubitemid 28450019)
126. Teppala S, Shankar A. Association between serum IGF-1 and diabetes among U.S. adults. Diabetes Care. 2010;33:2257-2259.
127. Rieder S, Michalski CW, Friess H, et al. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer. Anticancer Agents Med Chem. 2011;11(5):427-433.
128. Treins C, Giorgetti-Peraldi S, Murdaca J, et al. Regulation of vascular endothelial growth factor expression b advanced gl-cation end products. J Biol Chem. 2001;276:43836-43841.
129. Wang F, Li SS, Segersvard R, et al. H-poxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energ homeostasis. Am J Pathol. 2007;170:469-477. (Pubitemid 47339384)
130. Williams B, Gallacher B, Patel H, et al. Glucose-induced protein kinase C activation regulates vascular permeabilit factor mRNA expression and peptide production b human vascular smooth muscle cells in vitro. Diabetes. 1997;46:1497-1503. (Pubitemid 27369089)
131. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998. (Pubitemid 35363648)
132. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360. (Pubitemid 38680426)
133. Vesel MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunit to cancer. Annu Rev Immunol. 2011;29:235-271.
134. Samm N, Werner K, Ruckert F, et al. The role of apoptosis in the patholog of pancreatic cancer. Cancers. 2010;3:1-16.
135. Nagata S, Golstein P. The Fas death factor. Science. 1995;267:1449-1456.
136. Strand S, Hofmann WJ, Hug H, et al. L-mphoc-te apoptosis induced b CD95 (APO-1/Fas) ligand-expressing tumor cellsVa mechanism of immune evasion? Nat Med. 1996;2:1361-1366.
137. Ungefroren H, Voss M, Bernstorff WV, et al. Immunological escape mechanisms in pancreatic carcinoma. Ann N Acad Sci. 1999;880:243-251. (Pubitemid 29349133)
138. Ohta T, Elnemr A, Kitagawa H, et al. Fas ligand expression in human pancreatic cancer. Oncol Rep. 2004;12:749-754.
139. von BernstorffW, Spanjaard RA, Chan AK, et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surger-. 1999;125:73-84. (Pubitemid 29063174)
140. Sato T, Irie S, Kitada S, et al. FAP-1: a protein t-rosine phosphatase that associates with Fas. Science. 1995;268:411-415.
141. Bellone G, Smirne C, Carbone A, et al. Production and proYapoptotic activit of soluble CD95 ligand in pancreatic carcinoma. Clin Cancer Res. 2000;6:2448-2455. (Pubitemid 30399214)
142. Dhein J, Walczak H, Baumler C, et al. Autocrine T-cell suicide mediated b APO-1/(Fas/CD95). Nature. 1995;373:438-441.
143. Griffith TS, L-nch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10:559-563. (Pubitemid 28479189)
144. Pitti RM, Kirchhoff S, Krammer PH, et al. Genomic amplification of a deco receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699-703. (Pubitemid 29003951)
145. Scaffidi C, Kirchhoff S, Krammer PH, et al. Apoptosis signaling in l-mphoc-tes. Curr Opin Immunol. 1999;11:277-285.
146. Ibrahim SM, Ringel J, Schmidt C, et al. Pancreatic adenocarcinoma cell lines show variable susceptibilit to TRAIL-mediated cell death. Pancreas. 2001;23:72-79. (Pubitemid 32592079)
147. Boni R, Wellmann A, Man -G, et al. Expression of the proliferation and apoptosisYassociated CAS protein in benign and malignant cutaneous melanoc-tic lesions. Am J Dermatopathol. 1999;21:125-128. (Pubitemid 29162870)
148. Yoong KF, Afford SC, Randhawa S, et al. Fas/Fas ligand interaction in human colorectal hepatic metastases: a mechanism of hepatoc-te destruction to facilitate local tumor invasion. Am J Pathol. 1999;154:693-703. (Pubitemid 29122588)
149. Sanlioglu AD, Dirice E, Elpek O, et al. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas. 2008;36:385-393. (Pubitemid 351591581)
150. Sanlioglu AD, Dirice E, Elpek O, et al. High TRAIL death receptor 4 and deco receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients. Pancreas. 2009;38:154-160.
151. Hamacher R, Schmid RM, Saur D, et al. Apoptotic pathwys in pancreatic ductal adenocarcinoma. Mol Cancer. 2008;7:64.
152. Fulda S. Apoptosis pathwys and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med. 2009;13:1221-1227.
153. Ozawa F, Friess H, Kleeff J, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 2001;163:71-81. (Pubitemid 32121832)
154. Schuler S, Fritsche P, Diersch S, et al. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer. 2010;9:80.
155. Schuler S, Diersch S, Hamacher R, et al. SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis. Int J Oncol. 2011;38:219-225.
156. Huang S, Sinicrope FA. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther. 2010;9:742-750.
157. Ripka S, Neesse A, Riedel J, et al. CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut. 2010;59:1101-1110.
158. Kauh J, Fan S, Xia M, et al. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis b the histone deacet-lase inhibitor LBH589. PLoS One. 2010;5:e10376.
159. Wang P, Zhang J, Bellail A, et al. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal. 2007;19:2237-2246. (Pubitemid 47361680)
160. Murtaza I, Saleem M, Adhami VM, et al. Suppression of cFLIP b lupeol, a dietar triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res. 2009;69:1156-1165.
161. Vogler M, Durr K, Jovanovic M, et al. Regulation of TRAIL-induced apoptosis b XIAP in pancreatic carcinoma cells. Oncogene. 2007;26:248-257.
162. Vogler M, Walczak H, Stadel D, et al. Targeting XIAP b-passes Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res. 2008;68:7956-7965.
163. Vogler M, Walczak H, Stadel D, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activit in preclinical models of pancreatic carcinoma. Cancer Res. 2009;69:2425-2434.
164. Dineen SP, Roland CL, Greer R, et al. Smac mimetic increases chemotherap response and improves survival in mice with pancreatic cancer. Cancer Res. 2010;70:2852-2861.
165. Mori T, Doi R, Kida A, et al. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res. 2007;142:281-286. (Pubitemid 47418828)
166. Huang S, Okumura K, Sinicrope FA. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res. 2009;15:150-159.
167. Bai J, Sui J, Demirjian A, et al. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherap overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005;65:2344-2352. (Pubitemid 40490145)
168. Song JJ, An JY, Kwon -T, et al. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL. J Biol Chem. 2007;282:319-328. (Pubitemid 47076650)
169. Retzer-Lidl M, Schmid RM, Schneider G. Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int J Cancer. 2007;121:66-75. (Pubitemid 46753852)
170. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death b the human tumorYassociated antigen RCAS1. Nat Med. 1999;5:938-942. (Pubitemid 29372422)
171. Hiraoka K, Hida Y, MiYamoto M, et al. High expression of tumorYassociated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int J Cancer. 2002;99:418-423. (Pubitemid 34495856)
172. Ozkan H, Akar T, Koklu S, et al. Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliar diseases. Pancreatolog-. 2006;6:268-272. (Pubitemid 44329077)
173. Giaginis C, Davides D, Zarros A, et al. Clinical significance of tumorYassociated antigen RCAS1 expression in human pancreatic ductal adenocarcinoma. Dig Dis Sci. 2008;53:1728-1734. (Pubitemid 351624419)
174. Imanishi T, Kamigaki T, Nakamura T, et al. Correlation between expression of major histocompatibilit complex class I and that of antigen presenting machineries in carcinoma cell lines of the pancreas, biliar tract and colon. Kobe J Med Sci. 2006;52:85-95. (Pubitemid 44338393)
175. Pandha H, Rigg A, John J, et al. Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines. Clin Exp Immunol. 2007;148:127-135. (Pubitemid 46364984)
176. Groh V, Rhinehart R, Secrist H, et al. Broad tumorYassociated expression and recognition b tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A. 1999;96:6879-6884. (Pubitemid 29274978)
177. Marten A, von Lilienfeld-Toal M, Buchler MW, et al. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell c-totoxicit-. Int J Cancer. 2006;119:2359-2365. (Pubitemid 44546956)
178. Harris CL, Abbott RJ, Smith RA, et al. Molecular dissection of interactions between components of the alternative pathwy of complement and decy accelerating factor (CD55). J Biol Chem. 2005;280:2569-2578. (Pubitemid 40189359)
179. Purcell DF, Deacon NJ, Andrew SM, et al. Human non-lineage antigen, CD46 (HuL-m5): purification and partial sequencing demonstrates structural homolog with complement-regulating gl-coproteins. Immunogenetics. 1990;31:21-28. (Pubitemid 20034236)
180. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement l-sis restricting factor, inhibits C5b-8 catal-sed insertion of C9 into lipid bilyers. Immunolog-. 1990;71:1-9. (Pubitemid 20296064)
181. Juhl H, Helmig F, Baltzer K, et al. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibod 17-1A. J Surg Oncol. 1997;64:222-230. (Pubitemid 27157412)
182. Collins M, Ling V, Carreno BM. The B7 famil of immune-regulator ligands. Genome Biol. 2005;6:223.
183. Salomon B%, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulator pathwys in autoimmunit and transplantation. Annu Rev Immunol. 2001;19:225-252. (Pubitemid 32368035)
184. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 famil revisited. Annu Rev Immunol. 2005;23:515-548.
185. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261-268. (Pubitemid 33706004)
186. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitor receptor b-A novel B7 famil member leads to negative regulation of l-mphoc-te activation. J Exp Med. 2000;192:1027-1034.
187. Youngnak P, Kozono Y, Kozono H, et al. Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Bioph-s Res Commun. 2003;307:672-677. (Pubitemid 36944985)
188. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathwy in human pancreatic cancer. Clin Cancer Res. 2007;13:2151-2157. (Pubitemid 46649885)
189. Ishiwata K, Watanabe N, Guo M, et al. Costimulator B7-DC attenuates strong TH2 responses induced b Nippostrong-lus brasiliensis. J Immunol. 2010;184:2086-2094.
190. Loke P, Allison JP. PD-L1 and PD-L2 are differentiall regulated b TH1 and TH2 cells. Proc Natl Acad Sci U S A. 2003;100:5336-5341. (Pubitemid 36542706)
191. Matsumoto K, FukuYama S, Eguchi-Tsuda M, et al. B7-DC induced b IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem Bioph-s Res Commun. 2008;365:170-175. (Pubitemid 350102470)
192. Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitor pathwy affects both CD4(+) and CD8(+) T cells and is overcome b IL-2. Eur J Immunol. 2002;32:634-643. (Pubitemid 34257540)
193. Brown JA, Salama AD, Chitnis T, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and c-tokine production. J Immunol. 2003;170:1257-1266. (Pubitemid 36139491)
194. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathwy regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003;198:63-69. (Pubitemid 36870186)
195. Dong H, Strome SE, Salomao DR, et al. TumorYassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
196. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 b glioma cells: a potential mechanism of immune paral-sis. Cancer Res. 2003;63:7462-7467. (Pubitemid 37413489)
197. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves m-eloid dendritic cell-mediated antitumor immunit-. Nat Med. 2003;9:562-567. (Pubitemid 36597102)
198. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune s-stem and tumor immunotherap b PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293-12297.
199. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365-1369.
200. Tamura H, Dong H, Zhu G, et al. B7-H1 costimulation preferentiall enhances CD28-independent T-helper cell function. Blood. 2001;97:1809-1816. (Pubitemid 32217250)
201. Moore KW, de Waal Malef-t R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765. (Pubitemid 32368050)
202. Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunolog-. 2001;103:131-136. (Pubitemid 32521341)
203. Vicari AP, Trinchieri G. Interleukin-10 in viral diseases and cancer: exiting the lab-rinth? Immunol Rev. 2004;202:223-236. (Pubitemid 39576915)
204. Erdman SE, Rao VP, Poutahidis T, et al. CD4(+)CD25(+) regulator l-mphoc-tes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res. 2003;63:6042-6050. (Pubitemid 37187508)
205. Geng L, Huang D, Liu J, et al. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol. 2008;134:1021-1027.
206. Okudaira K, Hokari R, Tsuzuki Y, et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol. 2009;35:741-749.
207. Loos M, Hedderich DM, Friess H, et al. B7-H3 and its role in antitumor immunit-. Clin Dev Immunol. 2010;2010:683875.
208. Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulator molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2:269-274. (Pubitemid 33706005)
209. Sun M, Richards S, Prasad DV, et al. Characterization of mouse and human B7-H3 genes. J Immunol. 2002;168:6294-6297. (Pubitemid 34620050)
210. Steinberger P, Majdic O, Derdak SV, et al. Molecular characterization of human 4Ig-B7-H3, a member of the B7 famil with four Ig-like domains. J Immunol. 2004;172:2352-2359. (Pubitemid 38182383)
211. Zhang GB, Zhou H, Chen -J, et al. Characterization and application of two novel monoclonal antibodies against 2IgB7-H3: expression anal-sis of 2IgB7-H3 on dendritic cells and tumor cells. Tissue Antigens. 2005;66:83-92. (Pubitemid 41025929)
212. Roth TJ, Sheinin Y, Lohse CM, et al. B7-H3 ligand expression b prostate cancer: a novel marker of prognosis and potential target for therap-. Cancer Res. 2007;67:7893-7900. (Pubitemid 47281385)
213. Suh WK, Gajewska BU, Okada H, et al. The B7 famil member B7-H3 preferentiall down-regulates T helper t-pe 1-mediated immune responses. Nat Immunol. 2003;4:899-906. (Pubitemid 37098661)
214. Castriconi R, Dondero A, Augugliaro R, et al. Identification of 4Ig-B7-H3 as a neuroblastomaYassociated molecule that exerts a protective role from an NK cell-mediated l-sis. Proc Natl Acad Sci U S A. 2004;101:12640-12645. (Pubitemid 39122076)
215. Prasad DV, Ngu-en T, Li Z, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004;173:2500-2506. (Pubitemid 39063108)
216. Wang L, Fraser CC, Kikl K, et al. B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol. 2005;35:428-438. (Pubitemid 40331320)
217. Hashiguchi M, Kobori H, Ritprajak P, et al. Triggering receptor expressed on m-eloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci U S A. 2008;105:10495-10500.
218. Yamato I, Sho M, Nomi T, et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer. 2009;101:1709-1716.
219. Choi IH, Zhu G, Sica GL, et al. Genomic organization and expression anal-sis of B7-H4, an immune inhibitor molecule of the B7 famil-. J Immunol. 2003;171:4650-4654. (Pubitemid 37310581)
220. Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev. 2009;229:145-151.
221. Kr-czek I, Wei S, Zou L, et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulator T cells. J Immunol. 2006;177:40-44. (Pubitemid 43939113)
222. Kr-czek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203:871-881.
223. Kr-czek I, Wei S, Zhu G, et al. Relationship between B7-H4, regulator T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67:8900-8905. (Pubitemid 47437467)
224. Prasad DV, Richards S, Mai XM, et al. B7S1, a novel B7 famil member that negativel regulates T cell activation. Immunit-. 2003;18:863-873. (Pubitemid 36776433)
225. Sica GL, Choi IH, Zhu G, et al. B7-H4, a molecule of the B7 family, negativel regulates T cell immunit-. Immunit-. 2003;18:849-861.
226. Zang X, Loke P, Kim J, et al. B7x: a widel expressed B7 famil member that inhibits T cell activation. Proc Natl Acad Sci U S A. 2003;100:10388-10392. (Pubitemid 37071888)
227. Awadallah NS, Shro-er KR, Langer DA, et al. Detection of B7-H4 and p53 in pancreatic cancer: potential role as a c-tological diagnostic adjunct. Pancreas. 2008;36:200-206.
228. Paulie S, Ehlin-Henriksson B, Mellstedt H, et al. A p50 surface antigen restricted to human urinar bladder carcinomas and B l-mphoc-tes. Cancer Immunol Immunother. 1985;20:23-28. (Pubitemid 15238919)
229. Alderson MR, Armitage RJ, Tough TW, et al. CD40 expression b human monoc-tes: regulation b c-tokines and activation of monoc-tes b the ligand for CD40. J Exp Med. 1993;178:669-674. (Pubitemid 23218216)
230. Caux C, Burdin N, Galibert L, et al. Functional CD40 on B l-mphoc-tes and dendritic cells. Res Immunol. 1994;145:235-239, discussion 244-249. (Pubitemid 24268381)
231. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922. (Pubitemid 24140434)
232. MiYashita T, McIlraith MJ, Grammer AC, et al. Bidirectional regulation of human B cell responses b CD40-CD40 ligand interactions. J Immunol. 1997;158:4620-4633. (Pubitemid 127483780)
233. Merville P, Dechanet J, Desmouliere A, et al. Bcl-2+ tonsillar plasma cells are rescued from apoptosis b bone marrow fibroblasts. J Exp Med. 1996;183:227-236. (Pubitemid 26028762)
234. Henriquez NV, Floettmann E, Salmon M, et al. Differential responses to CD40 ligation among Burkitt l-mphoma lines that are uniforml responsive to Epstein-Barr virus latent membrane protein 1. J Immunol. 1999;162:3298-3307. (Pubitemid 29313577)
235. Hunter TB, Alsarraj M, Gladue RP, et al. An agonist antibod specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/l-mph node cell model. Scand J Immunol. 2007;65:479-486. (Pubitemid 46632548)
236. Shoji Y, MiYamoto M, Ishikawa K, et al. The CD40-CD154 interaction would correlate with proliferation and immune escape in pancreatic ductal adenocarcinoma. J Surg Oncol. 2011;103:230-238.
237. Alexandroff AB, Jackson AM, Paterson T, et al. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol. 2000;37:515-526. (Pubitemid 32001693)
238. Shorts L, Weiss JM, Lee JK, et al. Stimulation through CD40 on mouse and human renal cell carcinomas triggers c-tokine production, leukoc-te recruitment, and antitumor responses that can be independent of host CD40 expression. J Immunol. 2006;176: 6543-6552. (Pubitemid 43787836)
239. Georgopoulos NT, Merrick A, Scott N, et al. CD40-mediated death and c-tokine secretion in colorectal cancer: a potential target for inflammator tumour cell killing. Int J Cancer. 2007;121:1373-1381. (Pubitemid 47293808)
240. Beatt GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficac against pancreatic carcinoma in mice and humans. Science. 2011;331:1612-1616.
241. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol. 1999;66:876-888. (Pubitemid 30010511)
242. Rothlein R, Dustin ML, Marlin SD, et al. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol. 1986;137:1270-1274. (Pubitemid 16041114)
243. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med. 1996;74:13-33. (Pubitemid 26035754)
244. Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur C-tokine Netw. 2004;15:91-98. (Pubitemid 38980081)
245. Bo-d AW, Wawr-k SO, Burns GF, et al. Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc Natl Acad Sci U S A. 1988;85:3095-3099.
246. Van Seventer GA, Shimizu Y, Horgan KJ, et al. The LFA-1 ligand ICAM-1 provides an important costimulator signal for T cell receptor-mediated activation of resting T cells. J Immunol. 1990;144:4579-4586. (Pubitemid 20224088)
247. Elsner J, Sach M, Knopf HP, et al. S-nthesis and surface expression of ICAM-1 in pol-morphonuclear neutrophilic leukoc-tes in normal subjects and during inflammator disease. Immunobiolog-. 1995;193:456-464.
248. Mikloss J, Doudet DD, Schwab C, et al. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monke-s. Exp Neurol. 2006;197:275-283. (Pubitemid 43077135)
249. Roland CL, Harken AH, Sarr MG, et al. ICAM-1 expression determines malignant potential of cancer. Surger-. 2007;141:705-707. (Pubitemid 46863445)
250. Maruo Y, Gochi A, Kaihara A, et al. ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer. Int J Cancer. 2002;100:486-490.
251. Goodwin RG, Alderson MR, Smith CA, et al. Molecular and biological characterization of a ligand for CD27 defines a new famil of c-tokines with homolog to tumor necrosis factor. Cell. 1993;73:447-456. (Pubitemid 23143345)
252. Bowman MR, Crimmins MA, -etz-Aldape J, et al. The cloning of CD70 and its identification as the ligand for CD27. J Immunol. 1994;152:1756-1761. (Pubitemid 24075707)
253. Hintzen RQ, de Jong R, Lens SM, et al. CD27: marker and mediator of T-cell activation? Immunol Tody. 1994;15:307-311. (Pubitemid 24231744)
254. Hintzen RQ, Lens SM, Koopman G, et al. CD70 represents the human ligand for CD27. Int Immunol. 1994;6:477-480. (Pubitemid 24087241)
255. Jacquot S, Kobata T, Iwata S, et al. CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation b CD27 signaling. J Immunol. 1997;159:2652-2657. (Pubitemid 127681283)
256. Agematsu K, Nagumo H, Oguchi Y, et al. Generation of plasma cells from peripheral blood memor B cells: s-nergistic effect of interleukin-10 and CD27/CD70 interaction. Blood. 1998;91:173-180. (Pubitemid 28018742)
257. Hendriks J, Gravestein LA, Tesselaar K, et al. CD27 is required for generation and long-term maintenance of T cell immunit-. Nat Immunol. 2000;1:433-440.
258. Arens R, Tesselaar K, Baars PA, et al. Constitutive CD27/CD70 interaction induces expansion of effector-t-pe T cells and results in IFNgammymediated B cell depletion. Immunit-. 2001;15:801-812. (Pubitemid 34008507)
259. Tesselaar K, Arens R, van Schijndel GM, et al. Lethal T cell immunodeficienc induced b chronic costimulation via CD27-CD70 interactions. Nat Immunol. 2003;4:49-54. (Pubitemid 36104708)
260. Xiao Y, Hendriks J, Langerak P, et al. CD27 is acquired b primed B cells at the centroblast stage and promotes germinal center formation. J Immunol. 2004;172:7432-7441. (Pubitemid 38747605)
261. Hintzen RQ, Lens SM, Lammers K, et al. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol. 1995;154:2612-2623.
262. Lens SM, de Jong R, Hooibrink B, et al. Phenot-pe and function of human B cells expressing CD70 (CD27 ligand). Eur J Immunol. 1996;26:2964-2971. (Pubitemid 26411501)
263. Hishima T, FukaYama M, HaYashi Y, et al. CD70 expression in th-mic carcinoma. Am J Surg Pathol. 2000;24:742-746.
264. Bullock TN, Yagita H. Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J Immunol. 2005;174:710-717. (Pubitemid 40094264)
265. Agathanggelou A, Niedobitek G, Chen R, et al. Expression of immune regulator molecules in Epstein-Barr virusYassociated nasophar-ngeal carcinomas with prominent l-mphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating l-mphoid cells. Am J Pathol. 1995;147:1152-1160.
266. Lens SM, Drillenburg P, den Drijver BF, et al. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol. 1999;106:491-503. (Pubitemid 29450677)
267. Diegmann J, Junker K, Gerstmyer B, et al. Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma b gene expression profiling, real-time RT-PCR and immunohistochemistr-. Eur J Cancer. 2005;41:1794-1801. (Pubitemid 41132643)
268. Law CL, Gordon KA, Toki BE, et al. L-mphoc-te activation antigen CD70 expressed b renal cell carcinoma is a potential therapeutic target for anti-CD70 antibod-drug conjugates. Cancer Res. 2006;66:2328-2337.
269. RYan MC, Kostner H, Gordon KA, et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibod-drug conjugate SGN-75. Br J Cancer. 2010;103:676-684.
270. Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res. 1993;60:247-267.
271. Teraoka H, Sawada T, Yamashita Y, et al. TGF-beta1 promotes liver metastasis of pancreatic cancer b modulating the capacit of cellular invasion. Int J Oncol. 2001;19:709-715.
272. Sawada T, Kimura K, Nishihara T, et al. TGF-beta1 down-regulates ICAM-1 expression and enhances liver metastasis of pancreatic cancer. Adv Med Sci. 2006;51:60-65.
273. Hinz S, Pagerols-Ralu L, Oberg HH, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res. 2007;67:8344-8350. (Pubitemid 47395173)
274. Gum JR Jr. Mucin genes and the proteins the encode: structure, diversitY, and regulation. Am J Respir Cell Mol Biol. 1992;7:557-564.
275. Moniaux N, Escande F, Porchet N, et al. Structural organization and classification of the human mucin genes. Front Biosci. 2001;6:D1192-D1206.
276. Ro LD, Sahraei M, Subramani DB, et al. MUC1 enhances invasiveness of pancreatic cancer cells b inducing epithelial to mesench-mal transition. Oncogene. 2011;30:1449-1459.
277. Balague C, Gambus G, Carrato C, et al. Altered expression of MUC2, MUC4, and MUC5 mucin genes in pancreas tissues and cancer cell lines. Gastroenterolog-. 1994;106:1054-1061.
278. Balague C, Audie JP, Porchet N, et al. In situ h-bridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreas tissues. Gastroenterolog-. 1995;109:953-964.
279. Terada T, Ohta T, Sasaki M, et al. Expression of MUC apomucins in normal pancreas and pancreatic tumours. J Pathol. 1996;180:160-165. (Pubitemid 26370181)
280. Yonezawa S, B-rd JC, DahiYa R, et al. Differential mucin gene expression in human pancreatic and colon cancer cells. Biochem J. 1991;276(Pt 3):599-605.
281. Park HU, Kim JW, Kim GE, et al. Aberrant expression of MUC3 and MUC4 membraneYassociated mucins and sial-l Le(x) antigen in pancreatic intraepithelial neoplasia. Pancreas. 2003;26:e48-e54.
282. Nagata K, Horinouchi M, Saitou M, et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliar Pancreat Surg. 2007;14:243-254. (Pubitemid 46863913)
283. Monti P, Leone BE, Zerbi A, et al. Tumor-derived MUC1 mucins interact with differentiating monoc-tes and induce IL-10highIL-12low regulator dendritic cell. J Immunol. 2004;172:7341-7349. (Pubitemid 38747594)
284. Tinder TL, Subramani DB, Basu GD, et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol. 2008;181:3116-3125.
285. BesmerDM, Curr JM, Ro LD, et al. Pancreatic ductal adenocarcinoma (PDA) mice lacking Mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res. 2011;71(13):4432-4442.
286. Hoshi H, Sawada T, Uchida M, et al. TumorYassociated MUC5AC stimulates in vivo tumorigenicit of human pancreatic cancer. Int J Oncol. 2011;38:619-627.
287. Munn DH, Mellor AL. Indoleamine 2,3-diox-genase and tumor-induced tolerance. J Clin Invest. 2007;117:1147-1154.
288. Fallarino F, Grohmann U, You S, et al. The combined effects of tr-ptophan starvation and tr-ptophan catabolites down-regulate T cell receptor zetychain and induce a regulator phenot-pe in naive T cells. J Immunol. 2006;176:6752-6761. (Pubitemid 43787857)
289. Witkiewicz A, Williams TK, Cozzitorto J, et al. Expression of indoleamine 2,3-diox-genase in metastatic pancreatic ductal adenocarcinoma recruits regulator T cells to avoid immune detection. J Am Coll Surg. 2008;206:849-854; discussion 854-856.
290. Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation b macrophage tr-ptophan catabolism. J Exp Med. 1999;189:1363-1372. (Pubitemid 29227522)
291. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis b tr-ptophan catabolism. Cell Death Differ. 2002;9:1069-1077.
292. Chung JC, Oh MJ, Choi SH, et al. Proteomic anal-sis to identif biomarker proteins in pancreatic ductal adenocarcinoma. ANZ J Surg. 2008;78:245-251. (Pubitemid 351432692)
293. Camb I, Le Mercier M, Lefranc F, et al. Galectin-1: a small protein with major functions. Gl-cobiolog-. 2006;16:137R-157R. (Pubitemid 44530693)
294. Xue X, Lu Z, Tang D, et al. Galectin-1 secreted b activated stellate cells in pancreatic ductal adenocarcinoma stroma promotes proliferation and invasion of pancreatic cancer cells: an in vitro stud on the microenvironment of pancreatic ductal adenocarcinoma. Pancreas. 2011;40:832-839.
295. Cooper D, Ilarregui JM, Pesoa SA, et al. Multiple functional targets of the immunoregulator activit of galectin-1: control of immune cell trafficking, dendritic cell ph-siologY, and T-cell fate. Methods Enz-mol. 2010;480:199-244.
296. Simon HU, Haj-ehia A, Levi-Schaffer F. Role of reactive ox-gen species (ROS) in apoptosis induction. Apoptosis. 2000;5:415-418. (Pubitemid 32162623)
297. Kannan K, Jain SK. Oxidative stress and apoptosis. Pathoph-siolog-. 2000;7:153-163.
298. Davis W Jr, Ronai Z, Tew KD. Cellular thiols and reactive ox-gen species in drug-induced apoptosis. J Pharmacol Exp Ther. 2001;296:1-6. (Pubitemid 32015053)
299. Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Bioph-s. 2002;397:342-344. (Pubitemid 34852301)
300. Clement MV, Stamenkovic I. Superoxide anion is a natural inhibitor of FAS-mediated cell death. EMBO J. 1996;15:216-225. (Pubitemid 26029201)
301. Lin KI, Pasinelli P, Brown RH, et al. Decreased intracellular superoxide levels activate Sindbis virus-induced apoptosis. J Biol Chem. 1999;274:13650-13655.
302. Brar SS, Corbin Z, Kenned TP, et al. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. Am J Ph-siol Cell Ph-siol. 2003;285:C353-369. (Pubitemid 36917850)
303. Sauer H, Wartenberg M, Hescheler J. Reactive ox-gen species as intracellular messengers during cell growth and differentiation. Cell Ph-siol Biochem. 2001;11:173-186. (Pubitemid 32786086)
304. Chiarugi P, Pani G, Giannoni E, et al. Reactive ox-gen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK t-rosine phosphatase is required for cell adhesion. J Cell Biol. 2003;161:933-944. (Pubitemid 36718426)
305. Vaquero EC, Edderkaoui M, Pandol SJ, et al. Reactive ox-gen species produced b NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem. 2004;279:34643-34654. (Pubitemid 39318094)
306. Wehler T, Wolfert F, Schimanski CC, et al. Strong expression of chemokine receptor CXCR4 b pancreatic cancer correlates with advanced disease. Oncol Rep. 2006;16:1159-1164.
307. Shen R, -e Y, Chen L, et al. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One. 2008;3:e1652.
308. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor b human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096-1103. (Pubitemid 26338628)
309. Wong HH, Lemoine NR. Biological approaches to therap of pancreatic cancer. Pancreatolog-. 2008;8:431-461.
310. Andre F, Delaloge S, Soria JC. Biolog-driven phase II trials: what is the optimal model for molecular selection? J Clin Oncol. 2011;29:1236-1238.
311. Almhanna K, Philip PA. Defining new paradigms for the treatment of pancreatic cancer. Curr Treat Options Oncol. 2011;12(2):111-125.
312. O'Reill EM, Epstein AS. Recent findings in pancreatic cancer: illuminating emerging treatment strategies. 2010. Available at: http://cme.medscape.com/viewarticle/728727. Accessed August 1, 2010.
313. Dauer M, Herten J, Bauer C, et al. Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated c-totoxicit induced b tumor l-sate-pulsed dendritic cells. J Immunother. 2005;28:332-342. (Pubitemid 40962326)